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Background: Randomized controlled trials (RCTs) that are inappropriately designed or executed may provide
biased findings and mislead clinical practice. In view of recent interest in the treatment and prevention of
thrombotic complications in cancer patients we evaluated the characteristics, risk of bias and their time trends in
RCTs of anticoagulation in patients with cancer.
Methods: We conducted a comprehensive search, including a search of four electronic databases (MEDLINE,
EMBASE, ISI the Web of Science, and CENTRAL) up to February 2010. We included RCTs in which the intervention
and/or comparison consisted of: vitamin K antagonists, unfractionated heparin (UFH), low molecular weight heparin
(LMWH), direct thrombin inhibitors or fondaparinux. We performed descriptive analyses and assessed the
association between the variables of interest and the year of publication.
Results: We included 67 RCTs with 24,071 participants. In twenty one trials (31%) DVT diagnosis was triggered by
clinical suspicion; the remaining trials either screened for DVT or were unclear about their approach. 41 (61%), 22
(33%), and 11 (16%) trials respectively reported on major bleeding, minor bleeding, and thrombocytopenia. The
percentages of trials satisfying risk of bias criteria were: adequate sequence generation (85%), adequate allocation
concealment (61%), participants’ blinding (39%), data collectors’ blinding (44%), providers’ blinding (41%), outcome
assessors’ blinding (75%), data analysts’ blinding (15%), intention to treat analysis (57%), no selective outcome
reporting (12%), no stopping early for benefit (97%). The mean follow-up rate was 96%. Adequate allocation
concealment and the reporting of intention to treat analysis were the only two quality criteria that improved over
time.
Conclusions: Many RCTs of anticoagulation in patients with cancer appear to use insufficiently rigorous outcome
assessment methods and to have deficiencies in key methodological features. It is not clear whether this reflects a
problem in the design, conduct or the reporting of these trials, or both. Future trials should avoid the shortcomings
described in this article.Background
Venous thromboembolism (VTE), which includes deep
vein thrombosis (DVT) and pulmonary embolism (PE),
is a common disorder in patients with cancer [1]. It is
an important cause of morbidity and one of the leading
causes of death in that population [2].* Correspondence: elieakl@buffalo.edu
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reproduction in any medium, provided the orAnticoagulants are used for treatment of VTE and for
thromboprophylaxis in high risk conditions such as sur-
gery or the presence of an indwelling central venous
catheter [3-6]. A survival benefit from anticoagulants as
a result of VTE prevention and a possible direct antitu-
mor effect has also been explored [7,8].
High-quality randomized controlled trials (RCTs) are
the preferred method to establish the effects on efficacy
and safety outcomes, since they minimize systematic
error (bias). However, the reliability of their results
depends on the extent to which potential sources of bias
have been avoided [9]. Both the Cochrane Collaborationd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Rada et al. BMC Cancer 2013, 13:76 Page 2 of 8
http://www.biomedcentral.com/1471-2407/13/76and the GRADE working group have advanced the
methods to define which criteria should be evaluated in
order to judge the risk of bias of a trial or a body of
trials [9,10]. Poorly designed and/or conducted RCTs
may lead to biased results, mislead clinical practice and
adversely affect patients’ outcomes. Unfortunately, over-
whelming evidence shows the quality of RCTs is not
optimal [11].
A few studies assessing the quality or the reporting of
RCTs in patients with cancer have concluded that the
quality of reporting is low, and some suggest that it is
lower than in other areas [12-16]. However, we have
identified no study focusing on trials of anticoagulation
in patients with cancer.
The objective of this study is to systematically describe
the characteristics, the risk of bias and their time trends
in RCTs of anticoagulation in patients with cancer [3-8].
Methods
The study sample consists of all trials included in a
series of six Cochrane systematic reviews of anticoagula-
tion in patients with cancer [3-8]. The series covered the
majority of topics for which RCTs were conducted in
this field: parenteral anticoagulation for survival benefit
(VTE thromboprophylaxis trials in ambulatory patients
with cancer), oral anticoagulation for survival benefit,
central venous catheters thromboprophylaxis, periopera-
tive thromboprophylaxis, initial anticoagulation treat-
ment of VTE, and long term anticoagulation treatment
of VTE. A common search was conducted for all the
reviews.
Eligibility criteria
Inclusion criteria for this study were the following: stud-
ies describing random allocation; participants with can-
cer of any type or stage; intervention and/or comparison
consisting of vitamin K antagonists, unfractionated hep-
arin (UFH), low molecular weight heparin (LMWH),
ximelagatran, dabigatran, rivaroxaban, apixaban, or fon-
daparinux. We have included the details of the eligibility
criteria for each of the six Cochrane systematic reviews
in Additional file 1.
Search strategy
We electronically searched the following databases: the
Cochrane Central Register of Controlled Trials (CEN-
TRAL) (The Cochrane Library 2010, Issue 1), MEDLINE
(1966 to February 2010; accessed via Ovid), EMBASE
(1980 to February 2010; accessed via Ovid) and ISI Web
of Science (February 2010). The search strategies com-
bined free text and controlled vocabulary terms for can-
cer and anticoagulants, and a sensitive search strategy to
retrieve randomized clinical trials (available from theauthors). We have included the details of these elec-
tronic search strategies in Additional file 2.
In addition, we hand searched the conference proceed-
ings of the American Society of Clinical Oncology (ASCO,
starting with its first volume, 1982) and of the American
Society of Hematology (ASH, starting with its 2003 issue);
we screened the reference lists of included studies and of
other relevant systematic reviews; and we used the related
article feature in PubMed. We did not use language
restrictions. Detailed eligibility criteria for each systematic
review are reported in Additional file 1 [3-8].
Selection of studies
Two reviewers independently screened the titles and
abstracts of identified citations for potential eligibility.
Then, two reviewers independently screened the full text
of articles potentially eligible using a standardized form.
They resolved disagreements by discussion or by con-
sulting a third reviewer.
Data extraction
Two reviewers independently extracted the data in du-
plicate from each study. They used a standardized form
and resolved their disagreements by discussion or by
consulting a third author. We considered all available
reports for any particular trial to assess methodological
quality. We attempted to contact authors for missing or
unclearly reported data.
We extracted information about: publication year, lan-
guage, funding (governmental, for profit, not for profit),
population studied, number of participants, interven-
tions, outcomes and assessment methods of DVT and
PE (screening and diagnosis). Additionally, we evaluated
the following risk of bias criteria: adequacy of sequence
generation; adequacy of allocation concealment; blinding
of participants, providers, data collectors, outcome
assessors and data analysts; intention to treat analysis;
absence of selective outcome reporting; no early stop-
ping for benefit; and percentage of follow-up. For ques-
tions about blinding we further categorized unclearly
reported data into ‘probably yes’ and ‘probably no’ using
validated specific instructions (see Figure 1 in Akl et al.,
Journal of Clinical Epidemiology) [17].
Statistical analyses
We used frequency percentage, median and interquartile
range to describe the trials’ general characteristics and
risk of bias criteria. We also assessed temporal trends
for funding, number of participants, assessment meth-
ods, and outcome reporting.
Given that number of trials was not equally distributed
in time, with a small sample in the 80s, we assessed the as-
sociation between methodological quality criteria and the
year of publication using chi-square test for linear trend.
Figure 1 Study flow.
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interval since the publication of the oldest trial identified.
We assessed the association between industry funding and
risk of bias criteria using chi-square test. Also, we per-
formed regression analyses considering each of the risk of
bias criteria as the dependent variable and year, sample
size, review topic and funding as independent variables.
We performed all analyses using SPSS (version 17.0).Results
Search results
Figure 1 shows the study flow with reasons for exclu-
sions. The search identified 8187references, of which we
included sixty-seven unique RCTs, including a total of
24071 participants.Figure 2 Time trend of the number of randomized controlled trials evGeneral characteristics
The publication year was in the 1980s, 1990s, and 2000s
for 7%, 36% and 57% of trials respectively. Figure 2
shows the distribution by the year of publication from
1984 to 2010.
Tables 1 and 2 provide the general characteristics and
the methods of assessment of VTE in the studies.
English was the language of publication in 100% of
studies. The more common source of funding was pri-
vate for profit (n=41; 61%). Fourteen studies (21%) did
not report the funding source. No specific type of fund-
ing has increased or decreased significantly over time.
The median sample size was 156 participants (Q1-Q3:
74-355), having increased over time from 100 partici-
pants per trial (Q1-Q3: 52-352) before 1993 to 186 after
2001 (Q1-Q3: 88-385) (p<0.001).aluating anticoagulation in cancer.
Table 1 General characteristics of randomized controlled
trials
Overall, n (%) N=67
Funding source
governmental 12 (18)
private not for profit 3 (4)
private for profit 41 (61)
Private for profit plus other source 4 (6)
Not funded 3 (4)




Median (Q1-Q3) 156 (74-355)
n <200 39 (58)
n ≥200 28 (42)
Type of cancer
Participants with different cancer types 47 (70)
Cancer type not reported 5 (7)








Hematological and solid tumors 1 (6)




Vitamin K antagonist 20 (30)
Direct thrombin inhibitors 5 (7)
Fondaparinux 3 (4)
Comparator
Active treatment 47 (70)
Placebo 9 (13)
No treatment 11 (17)
LMWH=Low molecular weight heparin, UFH=Unfractioned Heparin,
VTE=Venous thromboembolism, PE=Pulmonary embolism, DVT=Deep
vein thrombosis.
Table 2 Assessment of VTE
Overall, n (%) N=67
Screening for DVT
Venography 31 (46)
125I-Fibrinogen-uptake test 14 (45)
Impedance plethysmography 7 (23)
Doppler Ultrasound 4 (13)
CT scan 5 (16)
No screening reported 1 (3)
36 (54)
Screening for PE
Ventilation/Perfusion Scan 6 (9)
Pulmonary Angiography 6 (100)
No screening reported 1 (15)
61 (91)
Diagnosis of clinically suspected DVT
Venography 51 (76)
125I-Fibrinogen-uptake test 44 (86)
Impedance plethysmography 4 (8)
Doppler Ultrasound 4 (8)
CT scan 30 (59)
Not reported 2 (4)
16 (24)
Diagnosis of clinically suspected PE
Ventilation/Perfusion Scan 44 (66)
CT of Thorax 40 (91)
Pulmonary Angiography 17 (39)
Autopsy 33 (75)







Major bleeding 41 (61)
Minor bleeding 22 (33)
Thrombocytopenia 11 (16)
CT= Computed tomography, VTE=Venous thromboembolism, PE=Pulmonary
embolism, DVT=Deep vein thrombosis.
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ferent types of cancer, while 15 (22%) included only one
type (lung, colorectal, gynecologic, prostate, breast, pan-
creatic, hematological, hematological and solid tumors).
The most frequently studied medication class was low
molecular weight heparin in 53 studies (79%). Ninestudies evaluated intervention against a placebo (13%).
The comparison with placebo was associated with later
years of publication (p=0.009).
Studies reported data for death, venous thrombo-
embolism, pulmonary embolism, and DVT in 53 (79%),
25 (37%), 31 (46%), and 38 (57%) of cases respectively.
Only 21 studies (31%) reported data on diagnosis
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DVT screening or did not report data. Assessments of
venous thromboembolism and of major bleeding were
associated with more recent years of publication
(p=0.002 and 0.001 respectively).
The number of trials reporting some method for the
screening of DVT decreased from 69 % in the first
period to 26% in the later period (p=0.005).
The use of the 125I-fibrinogen-uptake test, a test with
inferior diagnostic properties, was associated with earlier
publication (p<0.001). Use of Ventilation/Perfusion scan
as a screening tool was associated with earlier publica-
tion (p=0.01), and use of Doppler with diagnostic pur-
pose was associated with recent publication (p<0.001).
Reported risk of bias of RCTs
Table 3 describes the risk of bias of the included RCTs.
The reporting of only two risk of bias criteria has sig-
nificantly improved over time. Adequate allocation con-
cealment increased from 39% before 1993 to 71% after
2001 (p=0.046), and the reporting of an intention to
treat analysis increased from 31% to 77% (p=0.033). The
remaining risk of bias criteria did not significantly
change with the year of publication.
In the bivariable analysis, industry funding was signifi-
cantly associated with absence of caregiver blinding
(p=0.043) and use of intention to treat analysis (p=0.01).
Regression analysis showed that intention to treat was
significantly associated with type of funding (OR 0.172;
95% CI 0.046-0.648). None of the other risk of bias cri-
teria was significantly associated with type of funding,
review topic, year, or sample size.
Discussion
Our study describes the characteristics, the risk of bias
and the related time trends in randomized trials of antic-
oagulation in cancer. We used a comprehensive search
strategy and a systematic methodology for selecting
studies and abstracting data.
We found that the majority of RCTs of anticoagulation
in patients with cancer appear to use insufficiently rigor-
ous outcome assessment methods and to have deficiencies
in key methodological features. Specifically, included stud-
ies had low rates of blinding of participants and caregivers,
and intention to treat analysis. Our findings likely reflect a
problem in the design, conduct and the reporting of these
trials.
It has to be acknowledged it might be particularly chal-
lenging for trials of anticoagulation in the cancer setting,
relative to other types of interventions in other popula-
tions, to adhere to some of the methods employed to re-
duce the risk of bias. For example, clinicians caring for
patients with active cancer might be reluctant to accept to
be blinded given their patients are already at increased riskof bleeding, frequently undergo invasive procedures, and
might have chemotherapy-induce thrombocytopenia.
Our findings are consistent with those of several meth-
odological studies in cancer [12-16,18-23]. When im-
provement over time has been explored, they have also
found advances in some criteria, but at a rate slower
than expected [16,18]. One study suggested that report-
ing is the main problem in trials of radiation therapy in
oncology [13].
Given standard treatments have been established by
previous studies as effective and safe, 70% of included
trials had an active comparator (as opposed to placebo
or no intervention). In our assessment of risk of bias, we
did not consider the use of an active comparator as in-
appropriate. Rather, we focused on whether those
involved in the trial were blinded to allocation. While
blinding of providers and participants is feasible in these
cases, it is challenging in the situations where different
routes of administration are used, and dosage adjust-
ments are required. However, given the risk of bias asso-
ciated with a lack of blinding, this could be overcome
with double dummy designs, sham-adapted dosages and
several other techniques [24]. Considering that lack of
blinding can overestimate treatment effect estimates, it
is important to make every effort to ensure blinding in
studies [25]. Failure to report intention to treat analysis
can incorporate systematic and unpredictable bias in a
trial [26]. Other types of analysis (i.e. per protocol ana-
lysis) should not be presented in isolation. It is surpris-
ing that only the reporting of adequate allocation
concealment and of intention to treat analysis signifi-
cantly changed over time. However, and especially for
the latter, there is ample room for improvement.
Only 31% of studies reported data on diagnosis of deep
vein thrombosis triggered by clinical suspicion and the
rest reported data on DVT screening. However, estimat-
ing absolute symptomatic events from studies that
included screening may be misleading [27]. If screening
is positive, patients will typically receive anticoagulation.
If they had not received anticoagulation, some of them
would likely have developed symptomatic VTE. This
would underestimate the number of symptomatic VTE
and the benefit of any intervention that reduces VTE.
Bias in the opposite direction is also possible. A positive
screening test may lead to interpreting any minor symp-
tom, that otherwise might not have warranted investiga-
tion, as a symptomatic VTE. This would overestimate
the number of symptomatic VTE, and the benefit of any
intervention that reduces VTE. Others might argue that
screening-identified asymptomatic may be more inform-
ative than misleading. Indeed, there is evidence that inci-
dentally diagnosed PEs have similar prognostic value on
survival as symptomatic PEs [28,29]. Moreover, false
positive results should be minimized in the hands of
Table 3 Risk of bias in randomized controlled trials
Overall, n (%) N=67
Sequence generation
Adequate 57 (85)





Not clear 23 (34)
Participants blinded
Definitely yes 5 (8)
Probably yes 21 (31)
Probably no 13 (19)
Definitely no 28 (42)
Caregiver blinded
Definitely yes 5 (8)
Probably yes 22 (33)
Probably no 13 (19)
Definitely no 27 (40)
Data collector blinded
Definitely yes 3 (5)
Probably yes 26 (39)
Probably no 13 (19)
Definitely no 25 (37)
Outcome assessor blinded
Definitely yes 34 (51)
Probably yes 16 (24)
Probably no 7 (10)
Definitely no 10 (15)
Data analyst blinded
Definitely yes 7 (10)
Probably yes 3 (5)
Probably no 37 (55)





Free of selective reporting of
outcomes
Adequate 59 (88)




Table 3 Risk of bias in randomized controlled trials
(Continued)
For benefit 2 (3)
For harm 1 (2)
For insufficient accrual 4 (6)
Not reported 0 (0)
Follow up
Mean percentage (range) 96% (57-100)
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above concerns. More research is needed to shed more
light on this controversial area.
Interestingly, 20% of trials do not report the source of
funding. Of those who report, 3 of every 4 trials are com-
pletely or partially funded by private for profit sources. In-
dustry funded trials were more likely to report intention
to treat analysis, and less likely to report caregiver blind-
ing. It is well known that industry sponsored trials favor
products made by the company funding the research, but
one of the more likely explanations is not because a higher
risk of bias but through the selection of an inappropriate
comparator to the product being investigated [30,31].
We have found that the topic of the systematic review
not to be associated with risk of bias. While this might
reflect the absence of such association, it might be sim-
ply due to lack of statistical power given the relatively
small number of studies included in the analysis.
Implications for future trial conduct and reporting
Existing guidelines of reporting are widely available. Tri-
alists of anticoagulation in patients with cancer should
design more rigorous trials and transparently report
their methods and findings.
Implications for future methodological research
A recent systematic review found 177 studies evaluating
the methodological quality of RCTs. While this type of
studies is increasing, they suffer from a heterogeneity of
criteria used and lack of clear definitions. Our study ful-
fills most of the criteria of quality of reporting proposed
by these authors [32]. In the absence of other specific
guidelines for the reporting of this type of methodo-
logical reviews, these criteria could inform future work.
Conclusions
Many RCTs of anticoagulation in patients with cancer
appear to use insufficiently rigorous outcome assessment
methods and to have deficiencies in key methodological
features. It is not clear whether this reflects a problem in
the design, conduct or the reporting of these trials, or
both. Future trials should avoid the shortcomings
described in this article.
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